Head-to-head · free
Doximity, Inc. vs Eton Pharmaceuticals, Inc.
DOCS vs ETON — return on capital, cash generation, margins and balance sheet side by side.
DOCS
8 / 9
measures where DOCS leads
ETON
1 / 9
measures where ETON leads
A simple count of which company scores better on each measure — not a recommendation to buy or sell.
| Measure | DOCS · FY2026 | ETON · FY2025 |
|---|---|---|
| Revenue | $644.9M | $80.0M |
| Net income | $196.1M | (4.6M) |
| Revenue growth (yearly, multi-year) | 17.0% | 38.3% |
| Free cash flow | $326.5M | $10.2M |
| Free cash flow margin | 50.6% | 12.7% |
| Net cash / (debt) | — | — |
| ROIC | 16.4% | — |
| Return on equity | 19.3% | -18.2% |
| Gross margin | 89.1% | 53.5% |
| Operating margin | 33.3% | -1.1% |
| Net debt / EBITDA | -0.96x | 1.44x |
Figures are as reported by each company; latest fiscal year shown.
Where Doximity, Inc.'s cash went (FY2026)
- Capital spending
- $0
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Where Eton Pharmaceuticals, Inc.'s cash went (FY2025)
- Capital spending
- $333000
- Buybacks
- —
- Dividends
- —
- Acquisitions
- —
- Net debt issued / (repaid)
- —
Ask which business is stronger
"Which one reinvests at higher returns?" "Who carries more risk in its filings?" Get answers drawn straight from both companies' filings.
Compare them free